User:Raia Hasan/Sandbox 1
From Proteopedia
| Line 14: | Line 14: | ||
Botulinum Neurotoxins A is the first type of toxin to be introduced into the cosmetic world with the abbreviated name, Botox. Botox is mainly used for treating facial imperfections, muscle spasms, and other conditions like chronic migraines, dystonia, blepharospasms, diabetic neuropathy, spinal cord injury, epicondylitis incontinence, hyperhidrosis, and many more. | Botulinum Neurotoxins A is the first type of toxin to be introduced into the cosmetic world with the abbreviated name, Botox. Botox is mainly used for treating facial imperfections, muscle spasms, and other conditions like chronic migraines, dystonia, blepharospasms, diabetic neuropathy, spinal cord injury, epicondylitis incontinence, hyperhidrosis, and many more. | ||
| - | The mechanism of action for type A: Consists of a heavy chain (100 kDa) and light chain (50 kDa) which are linked together by a single disulfide bond. It is a 150- kDa molecular weight protein that inhibits the release of acetylcholine by blocking the neuromuscular communications and transmissions on motor and sympathetic nerve terminals. The heavy chain binds at the pre-synaptic surface of cholinergic neurons. They bind one way and are irreversible. Endocytosis allows for the toxin receptor- complex to be sent into the cell after binding. The botulism toxin enters the cytoplasm after the disulfide bond between the two chains is broken. The light chain interacts with SNAP-25 (needed for binding/ attachment and release of ACH from vesicles) specifically at the nerve terminal to prevent binding of acetylcholine vesicles with the cell membrane. <ref name= | + | The mechanism of action for type A: Consists of a heavy chain (100 kDa) and light chain (50 kDa) which are linked together by a single disulfide bond. It is a 150- kDa molecular weight protein that inhibits the release of acetylcholine by blocking the neuromuscular communications and transmissions on motor and sympathetic nerve terminals. The heavy chain binds at the pre-synaptic surface of cholinergic neurons. They bind one way and are irreversible. Endocytosis allows for the toxin receptor- complex to be sent into the cell after binding. The botulism toxin enters the cytoplasm after the disulfide bond between the two chains is broken. The light chain interacts with SNAP-25 (needed for binding/ attachment and release of ACH from vesicles) specifically at the nerve terminal to prevent binding of acetylcholine vesicles with the cell membrane. <ref name=prot>Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0</ref> |
| Line 78: | Line 78: | ||
<ref name=spores>Lakna. (2018, July 16). Difference between spore-forming bacteria and non-spore-forming bacteria. Pediaa.Com. Retrieved April 27, 2022</ref> | <ref name=spores>Lakna. (2018, July 16). Difference between spore-forming bacteria and non-spore-forming bacteria. Pediaa.Com. Retrieved April 27, 2022</ref> | ||
<ref name=WHO>World Health Organization. (2018, January 10). Botulism. World Health Organization. Retrieved May 2, 2022, from https://www.who.int/news-room/fact-sheets/detail/botulism</ref> | <ref name=WHO>World Health Organization. (2018, January 10). Botulism. World Health Organization. Retrieved May 2, 2022, from https://www.who.int/news-room/fact-sheets/detail/botulism</ref> | ||
| - | <ref name= | + | <ref name=prot>Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0</ref> |
<ref name=allergen>PMID: 26706467</ref>Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123 | <ref name=allergen>PMID: 26706467</ref>Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123 | ||
Revision as of 17:57, 2 May 2022
Botulinum Neurotoxin
| |||||||||||
References
- ↑ Lakna. (2018, July 16). Difference between spore-forming bacteria and non-spore-forming bacteria. Pediaa.Com. Retrieved April 27, 2022
- ↑ Patil S, Willett O, Thompkins T, Hermann R, Ramanathan S, Cornett EM, Fox CJ, Kaye AD. Botulinum Toxin: Pharmacology and Therapeutic Roles in Pain States. Curr Pain Headache Rep. 2016 Mar;20(3)http://dx.doi.org/10.1007/s11916-016-0545-0
- ↑ 3.0 3.1 3.2 3.3 World Health Organization. (2018, January 10). Botulism. World Health Organization. Retrieved May 2, 2022, from https://www.who.int/news-room/fact-sheets/detail/botulism
- ↑ How botox® is injected. The Cosmetic Skin Clinic. (2021, November 2). Retrieved April 27, 2022, from https://www.cosmeticskinclinic.com/advice-centre/how-botox-is-injected
[5]Mayo Foundation for Medical Education and Research. (2021, September 3). Cervical dystonia. Mayo Clinic. Retrieved April 27, 2022, from https://www.mayoclinic.org/diseases-conditions/cervical-dystonia/symptoms-causes/syc-20354123
[5]Naumann M, Jankovic J: Safety of botulinum toxin type A: a systematic review and meta-analysis. Curr Med Res Opin. 2004 Jul;20(7):981-90. doi: 10.1185/030079904125003962. [Article]
[5]Oliveira, Ademar Francisco de Filho et al. “Application of botulinum toxin to treat sialorrhea in amyotrophic lateral sclerosis patients: a literature review.” Einstein (Sao Paulo, Brazil) vol. 14,3 (2016): 431-434. doi:10.1590/S1679-45082016RB3594
[5]Pellett, S., Tepp, W. H., Scherf, J. M., Pier, C. L., & Johnson, E. A. (2015). Activity of botulinum neurotoxin type D (strain 1873) in human neurons. Toxicon : official journal of the International Society on Toxinology, 101, 63–69. https://doi.org/10.1016/j.toxicon.2015.04.015
[5]Product Monograph: Botox (Clostridium botulinum type A neurotoxin complex ) powder for injectable solution [Link]https://pediaa.com/difference-between-spore-forming-bacteria-and-non-spore-forming-bacteria/
[5]Simpson, L. L., Maksymowych, A. B., & Hao, S. (2001). The role of zinc binding in the biological activity of botulinum toxin. The Journal of biological chemistry, 276(29), 27034–27041. https://doi.org/10.1074/jbc.M102172200 FDA Approved Products: Botox (onabotulinumtoxinA) for injection [Link]
